Hui Chen , Xin Wang , Lianyou Zheng , Lingling Shi , Zhaoliang Chen , Lei Zhang , Yan Zhang , Qiansong Gao , Jie Wang , Zhuoqi Zhang , Zhendong Guo , Jinbao Xiang
{"title":"具有抗sars - cov -2活性的异恶唑嘧啶衍生物的模块化合成","authors":"Hui Chen , Xin Wang , Lianyou Zheng , Lingling Shi , Zhaoliang Chen , Lei Zhang , Yan Zhang , Qiansong Gao , Jie Wang , Zhuoqi Zhang , Zhendong Guo , Jinbao Xiang","doi":"10.1016/j.bioorg.2025.108992","DOIUrl":null,"url":null,"abstract":"<div><div>A highly efficient synthetic route for the preparation of isoxazolopyrimidine derivatives has been developed, characterized by mild reaction conditions, operational simplicity and high yields. Building on this, we further functionalized the isoxazolopyrimidine scaffold to synthesize 7-morpholinoisoxazolo[4,5-<em>d</em>]pyrimidine derivatives. <em>In vitro</em> evaluations revealed that compounds <strong>5a</strong> and <strong>6</strong><strong>g</strong> demonstrated significant anti-SARS-CoV-2 activity. Mechanistic studies indicated that the antiviral effects of <strong>5a</strong> and <strong>6</strong><strong>g</strong> were mediated through the inhibition of PI3K<em>δ</em> kinase, highlighting their potential as targeted therapeutic agents. Moreover, <em>in vivo</em> experiments conducted in a golden hamster model demonstrated that compound <strong>5a</strong> effectively suppressed SARS-CoV-2 replication in lung tissue, underscoring its therapeutic potential for combating COVID-19. These findings collectively suggest that isoxazolopyrimidine derivatives, particularly <strong>5a</strong>, represent promising candidates for further development as anti-SARS-CoV-2 therapeutics.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"165 ","pages":"Article 108992"},"PeriodicalIF":4.7000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Modular synthesis of isoxazolopyrimidine derivatives with anti-SARS-CoV-2 activity\",\"authors\":\"Hui Chen , Xin Wang , Lianyou Zheng , Lingling Shi , Zhaoliang Chen , Lei Zhang , Yan Zhang , Qiansong Gao , Jie Wang , Zhuoqi Zhang , Zhendong Guo , Jinbao Xiang\",\"doi\":\"10.1016/j.bioorg.2025.108992\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>A highly efficient synthetic route for the preparation of isoxazolopyrimidine derivatives has been developed, characterized by mild reaction conditions, operational simplicity and high yields. Building on this, we further functionalized the isoxazolopyrimidine scaffold to synthesize 7-morpholinoisoxazolo[4,5-<em>d</em>]pyrimidine derivatives. <em>In vitro</em> evaluations revealed that compounds <strong>5a</strong> and <strong>6</strong><strong>g</strong> demonstrated significant anti-SARS-CoV-2 activity. Mechanistic studies indicated that the antiviral effects of <strong>5a</strong> and <strong>6</strong><strong>g</strong> were mediated through the inhibition of PI3K<em>δ</em> kinase, highlighting their potential as targeted therapeutic agents. Moreover, <em>in vivo</em> experiments conducted in a golden hamster model demonstrated that compound <strong>5a</strong> effectively suppressed SARS-CoV-2 replication in lung tissue, underscoring its therapeutic potential for combating COVID-19. These findings collectively suggest that isoxazolopyrimidine derivatives, particularly <strong>5a</strong>, represent promising candidates for further development as anti-SARS-CoV-2 therapeutics.</div></div>\",\"PeriodicalId\":257,\"journal\":{\"name\":\"Bioorganic Chemistry\",\"volume\":\"165 \",\"pages\":\"Article 108992\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioorganic Chemistry\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0045206825008727\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic Chemistry","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0045206825008727","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Modular synthesis of isoxazolopyrimidine derivatives with anti-SARS-CoV-2 activity
A highly efficient synthetic route for the preparation of isoxazolopyrimidine derivatives has been developed, characterized by mild reaction conditions, operational simplicity and high yields. Building on this, we further functionalized the isoxazolopyrimidine scaffold to synthesize 7-morpholinoisoxazolo[4,5-d]pyrimidine derivatives. In vitro evaluations revealed that compounds 5a and 6g demonstrated significant anti-SARS-CoV-2 activity. Mechanistic studies indicated that the antiviral effects of 5a and 6g were mediated through the inhibition of PI3Kδ kinase, highlighting their potential as targeted therapeutic agents. Moreover, in vivo experiments conducted in a golden hamster model demonstrated that compound 5a effectively suppressed SARS-CoV-2 replication in lung tissue, underscoring its therapeutic potential for combating COVID-19. These findings collectively suggest that isoxazolopyrimidine derivatives, particularly 5a, represent promising candidates for further development as anti-SARS-CoV-2 therapeutics.
期刊介绍:
Bioorganic Chemistry publishes research that addresses biological questions at the molecular level, using organic chemistry and principles of physical organic chemistry. The scope of the journal covers a range of topics at the organic chemistry-biology interface, including: enzyme catalysis, biotransformation and enzyme inhibition; nucleic acids chemistry; medicinal chemistry; natural product chemistry, natural product synthesis and natural product biosynthesis; antimicrobial agents; lipid and peptide chemistry; biophysical chemistry; biological probes; bio-orthogonal chemistry and biomimetic chemistry.
For manuscripts dealing with synthetic bioactive compounds, the Journal requires that the molecular target of the compounds described must be known, and must be demonstrated experimentally in the manuscript. For studies involving natural products, if the molecular target is unknown, some data beyond simple cell-based toxicity studies to provide insight into the mechanism of action is required. Studies supported by molecular docking are welcome, but must be supported by experimental data. The Journal does not consider manuscripts that are purely theoretical or computational in nature.
The Journal publishes regular articles, short communications and reviews. Reviews are normally invited by Editors or Editorial Board members. Authors of unsolicited reviews should first contact an Editor or Editorial Board member to determine whether the proposed article is within the scope of the Journal.